RATIONALE: Serotonergic mechanisms are thought to play an important role in the regulation of mood, motor activity and sleep patterns. Serotonin reuptake is controlled by the serotonin transporter (5-HTT) and by a common functional insertion/deletion polymorphism in the corresponding gene's promoter region (5-HTTLPR). Homozygosity for the long variant may confer a favourable response to treatment with serotonin reuptake inhibitors (SSRIs), and to sleep deprivation. OBJECTIVES: The study assessed the role of the 5-HTTLPR genotype in determining motor side effects of antidepressant medication. METHODS: Motor activity patterns of 62 patients with major depression who were being treated with either SSRIs or tricyclic antidepressants (TCAs) were monitored over a 24-h period using a wrist-actograph. Additionally, motor activity was rated in a semi-structured interview using the motor agitation and retardation scale (MARS). RESULTS: Night-time motor activity was significantly increased in homozygous carriers of the long 5-HTTLPR allele (LL-genotype) who were being treated with SSRIs in comparison to short allele carriers (LS-genotype and SS-genotype), regardless of the type of antidepressant treatment (P<0.001). It was also significantly increased in comparison to patients with the LL-genotype who were being treated with TCAs (P<0.01). Differences in actographic motor activity were most prominent between 11 p.m. and 4 a.m. Clinical ratings of motor activity also showed a trend toward higher agitation scores in patients with the LL-genotype who received SSRI treatment. CONCLUSIONS: Homozygosity for the long variant of the 5-HTTLPR may cause a predisposition to increased night-time motor activity in conjunction with SSRI treatment.
RATIONALE: Serotonergic mechanisms are thought to play an important role in the regulation of mood, motor activity and sleep patterns. Serotonin reuptake is controlled by the serotonin transporter (5-HTT) and by a common functional insertion/deletion polymorphism in the corresponding gene's promoter region (5-HTTLPR). Homozygosity for the long variant may confer a favourable response to treatment with serotonin reuptake inhibitors (SSRIs), and to sleep deprivation. OBJECTIVES: The study assessed the role of the 5-HTTLPR genotype in determining motor side effects of antidepressant medication. METHODS: Motor activity patterns of 62 patients with major depression who were being treated with either SSRIs or tricyclic antidepressants (TCAs) were monitored over a 24-h period using a wrist-actograph. Additionally, motor activity was rated in a semi-structured interview using the motor agitation and retardation scale (MARS). RESULTS: Night-time motor activity was significantly increased in homozygous carriers of the long 5-HTTLPR allele (LL-genotype) who were being treated with SSRIs in comparison to short allele carriers (LS-genotype and SS-genotype), regardless of the type of antidepressant treatment (P<0.001). It was also significantly increased in comparison to patients with the LL-genotype who were being treated with TCAs (P<0.01). Differences in actographic motor activity were most prominent between 11 p.m. and 4 a.m. Clinical ratings of motor activity also showed a trend toward higher agitation scores in patients with the LL-genotype who received SSRI treatment. CONCLUSIONS: Homozygosity for the long variant of the 5-HTTLPR may cause a predisposition to increased night-time motor activity in conjunction with SSRI treatment.
Authors: B G Pollock; R E Ferrell; B H Mulsant; S Mazumdar; M Miller; R A Sweet; S Davis; M A Kirshner; P R Houck; J A Stack; C F Reynolds; D J Kupfer Journal: Neuropsychopharmacology Date: 2000-11 Impact factor: 7.853
Authors: L Kathryn Durham; Suzin M Webb; Patrice M Milos; Cathryn M Clary; Albert B Seymour Journal: Psychopharmacology (Berl) Date: 2003-09-04 Impact factor: 4.530
Authors: Thomas C Baghai; Cornelius Schule; Peter Zwanzger; Peter Zill; Robin Ella; Daniela Eser; Tobias Deiml; Christo Minov; Rainer Rupprecht; Brigitta Bondy Journal: World J Biol Psychiatry Date: 2003-07 Impact factor: 4.132
Authors: Bryan Maloney; Balmiki Ray; Elizabeth P Hayden; John I Nurnberger; Debomoy K Lahiri Journal: Psychiatr Genet Date: 2009-04 Impact factor: 2.458
Authors: Turhan Canli; Kazufumi Omura; Brian W Haas; Andreas Fallgatter; R Todd Constable; Klaus Peter Lesch Journal: Proc Natl Acad Sci U S A Date: 2005-08-10 Impact factor: 11.205
Authors: Regina Bussing; Adam M Reid; Joseph P H McNamara; Johanna M Meyer; Andrew G Guzick; Dana M Mason; Eric A Storch; Tanya K Murphy Journal: Psychiatry Res Date: 2014-12-10 Impact factor: 3.222
Authors: Beverly H Brummett; Andrew D Krystal; Allison Ashley-Koch; Cynthia M Kuhn; Stephan Züchner; Ilene C Siegler; John C Barefoot; Edna L Ballard; Lisa P Gwyther; Redford B Williams Journal: Psychosom Med Date: 2007-08-31 Impact factor: 4.312
Authors: Dennis L Murphy; Meredith A Fox; Kiara R Timpano; Pablo R Moya; Renee Ren-Patterson; Anne M Andrews; Andrew Holmes; Klaus-Peter Lesch; Jens R Wendland Journal: Neuropharmacology Date: 2008-09-11 Impact factor: 5.250